Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On January 5, 2026, Compass Therapeutics, Inc. (Nasdaq: CMPX), a Boston-based biopharmaceutical company focused on oncology, announced the granting of stock options to two newly appointed executives under its 2025 Inducement Plan. This move aligns with Nasdaq Listing Rule 5635(c)(4) as these inductions were made as a material motivation for their continued employment with the company.

The company has awarded non-qualified stock options for 1,000,000 shares of common stock each to its new Chief Commercial Officer, Arjun Prasad, and Chief Medical Officer, Cynthia Sirard. The exercise price for these options was set at $5.17 per share—matching the closing stock price on January 2, 2026. The options come with a 10-year term and are structured with a four-year vesting schedule: 25% will vest after one year, followed by 75% vesting in equal monthly increments over the subsequent three years, contingent upon the executives’ ongoing service.

Compass Therapeutics, founded in 2014, specializes in developing antibody-based therapeutics targeting various human diseases, primarily cancers. The company aims to enhance anti-tumor responses by focusing on angiogenesis, immune system interaction, and tumor growth mechanisms. Their innovative pipeline is designed to intersect therapeutic pathways that are critical for combating tumors, employing strategies such as targeting microvasculature, stimulating immune responses, and counteracting immunosuppressive tactics employed by tumors.

As Compass Therapeutics progresses its clinical development and seeks commercialization for its product candidates, the recent executive appointments and inducement grants are strategically positioned to drive the company’s mission forward in a competitive biopharmaceutical landscape. For additional information, visit Compass Therapeutics’ website or contact their investor relations and media representatives.

Compass Therapeutics, Inc. (Nasdaq: CMPX) recently announced the grant of stock options to its two newly appointed executives, demonstrating its commitment to aligning employee performance with shareholder value. Each of the new hires, Chief Commercial Officer Arjun Prasad and Chief Medical Officer Cynthia Sirard, received non-qualified stock options for 1,000,000 shares with an exercise price of $5.17, reflecting the company’s current stock price. This grant acts as a significant incentive for the new executives, signaling the company's focus on talent acquisition to support its ambitious oncology-focused drug development goals.

From a market perspective, the exercise price being equal to the stock's recent closing price suggests a strategic move to retain valuable talent. Since the options will vest over four years, with an initial 25% vesting after one year, it promotes sustained performance and aligns their interests with long-term company growth. Investors should view this positively, as strong leadership can enhance the company's execution capabilities in a competitive biotech landscape.

Investors may want to consider the potential impact of Compass’s pipeline development on future revenue streams. The firm's focus on proprietary antibody-based therapeutics positions it well in an oncology market that is ripe for innovation. Additionally, the successful appointment of key executives may signal a heightened trajectory in clinical development and commercialization efforts of their candidate products.

As a result, those looking to invest might perceive CMPX as an attractive opportunity, especially if the company can translate its promising pipeline into tangible results. However, be mindful of the inherent volatility in biotech stocks, particularly those in clinical stages. Continued monitoring of Compass Therapeutics’ operational progress and market conditions will be essential for making informed investment decisions.